Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07918417). This is a study registration, not published results. Lead sponsor: European University Miguel de Cervantes. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 48 participants (ESTIMATED). Conditions: Alzheimer's Dementia (AD), Alzheimer Disease (AD). Interventions: OTHER: High load; OTHER: Moderate load; OTHER: Healthy adults - High load; OTHER: Healthy adults - Moderate load. Primary outcome measures: Gut microbiome , Baseline, week 12 of intervention; Inflammation indices - Systemic Inflammation Response Index , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining; Plasma biomarkers - Brain-derived neurotrophic factor , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining; Inflammation indices - Aggregate Index of Systemic Inflammation , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining; Plasma biomarkers - p-tau217 , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining; Plasma biomarkers - Klotho , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining; Plasma biomarkers - Testosterone/cortisol ratio , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining; Biological age , Baseline, week 1 of intervention, week 12 of intervention and week 12 of detraining. Brief summary: Alzheimer's disease (AD) is the leading cause of dementia worldwide and involves systemic alterations beyond the brain, such as loss of muscle strength, chronic low-grade inflammation, and gut microbiome dysbiosis. Physical exercise is a promising non-pharmacological therapy, and velocity-based resistance training has proven safe and effective in older adults. However, the effects of performing resistance exercises at high versus moderate velocity in people with AD remain unknown, and human evidence on how exercise modulates the gut microbiome in AD is very limited. This study aims to assess and compare the effects of two velocity-based resistance training modalities (high load at moderate velocity and moderate load at high velocity) versus usual care on the gut microbiome, systemic inflammation, plasma biomarkers, biological age, and intrinsic capacity in older adults with mild-to-moderate AD, using cognitively healthy older adults as a reference group.